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ABSTRACT (Continue on reverse if necessary and identify by block number)
The mutagenic potential of PHYSOSTIGMINE SALICYLATE was assessed in the Ames Test both in the presence and absence of a 10% liver S-9 activation mixture. Tester strains TA97, TA98, TAI00, TAI04, TA1535, TA1537, and TA1538 were exposed to doses ranging from 2 x 10-1 mg/plate to 6.4 x 10 -5 mg/plate. The test compound was not mutagenic under the conditions of this test.
A copy of the final report, study protocol, retired SOPs, stability and purity data on the test compound, and an aliquot of the test compound will be retained in the LAIR Archives. 
INTRODUCTION
This laboratory has reported that physostigmine salicylate is not mutagenic in the Ames Salmonella/Mammalian Microsome Mutagenicity Test (1).
In this assay, a standard 4% concentration of liver S-9 fraction in the activated plates was used. It has been recommended chat if a test compound is negative in the activated assay with the standard concentration of S-9, it should be retested at a 10% concentration of liver S-9 fraction (2).
Since physostigmine produced a positive response in the mouse lymphoma assay (3), and sister chromatid exchange assays (4), a retest of physostigmine salicylate in the Ames Test was conducted using the recommended high concentration of liver S-9.
The Ames Salmonella/Mammalian Microsome Mutagenicity Test is a short-term screening test that utilizes histidine auxotrophic mutant strains of Salmonella typhimurium to detect compounds that are potentially mutagenic in mammals. A mammalian microsomal enzyme system is incorporated in the test to increase sensitivity by simulating in vivo metabolic activation of the test compound. The Ames test is an inexpensive yet highly predictive and reliable test for detecting mutagenic activity anq thus carcinogenic potential (5).
This evaluation of PHYSOSTIGMINE SALICYLATE utilizes a revision of the Ames Salmonella/Mammalian Microsome Mutagenicity Test (2) .
Objective of the Study
The objective of this study was to determine the mutagenic potential of PHYSOSTIGMINE SALICYLATE in an Ames Salmonella/Mammalian Microsome Mutagenicity Test which utilized a concentration of 10% liver S-9 in the activation mixture. 
MATERIALS AND METHODS
Test Compound
Tst Solvent
The positive control chemicals and the test compound were dissolved in grade I dimethyl sulfoxide (lot 113F-0450) obtained from Sigma Chemical Co. (St. Louis, MO). The glassdistilled water used in this assay was first passed through a Technic Series 300 Reverse Osmosis Unit (Seattle, WA), then through a Corning MP-I Mega-Pure System glass distillation unit (Corning Glass Works, Corning, NY) (6).
Chemical Preparation
On the day of dosing, 300 mg of the test compound was measured into a sterile vial and dissolved in dimethyl sulfoxide to achieve a 10% (w/v) solution. Aliquots of this solution were used to dose the test plates.
Test Strains
Salmonella strains TA97, TA98, TA100, TAI04, TA1535, TA1537, and TA1538 obtained directly from Dr. Bruce Ames, University of California, Berkeley, were used. These strains were maintained in our laboratory in liquid nitrogen. Quality control tests were run concurrently with the test substance to establish the validity of each strain's special features and to determine the spontaneous reversion rate. Descriptions of the strains, their genetic markers, and the methods for strain validation are given in the LAIR SOP, OP-STX-l (7).
Test Format PHYSOSTIGMINE SALICYLATE was evaluated for mutagenic potential according to the revised Ames method (2).
A detailed description of the methodology is given in LAIR SOP, OP-STX-l (7).
Toxicity Tests
Toxicity tests were conducted to determine a sublethal concentration of the test substance ( Table 1) .
This toxicity level was found by using minimal glucose agar (MGA) plates, concentrations of test compound ranging from 1.6 x 10 -3 mg/plate to 5.0 mg/plate, and approximately 108 cells of TA100 per plate. Top agar containing trace amounts of histidine and biotin was placed on the plates. Strain verification was confirmed on the bacteria, along with a determination of the spontaneous reversion rate. After incubation, the growth on the plates was observed. Since the two highest doses showed a decrease in the number of macrocolonies (below the number in the spontaneous reversion plates) or an observable reduction in the density of the background lawn, a maximium limit dose of 0.2 mg/plate was used in the mutagenicity test.
Mutagenicity Test
The test substance was evaluated over a 1000-fold range of concentrations, decreasing from the minimum toxic level (the maximum or limit dose) by a dilution factor of 5, both with and without 0.5 ml of the S-9 microsome fraction. The S-9 was purchased from Microbiological Associates, Inc. (Bethesda, MD).
After all the ingredients were added, the top agar was mixed, then overlaid on MGA plates. These plates contained 2% glucose and Vogel Bonner "E" Concentrate (8) . The water used in this medium and in all reagents came from a Technic Model 301 Reverse Osmosis Pre-Treatment Water System (Seattle, WA) (6).
Plates were incubated upside down in the dark at 37'C for 72 hours (Maron, 1985, personal communication) .
Plates were prepared in triplicate and the individual revertant counts were recorded. The average number of revertants at each dose level was compared to the average number of spontaneous revertants (negative control).
The spontaneous reversion rate (with and-without S-9) was monitored by averaging the counts from two determinations run simultaneously with the test compound. The spontaneous reversion rate was determined by inoculating one set of plates before and one set after the test compound plates so that any chanqe in spontaneous reversion rate during the dosing urocedure would be detected. This spontaneous reversion rate was also compared with historical values for this laboratory and those cited in Maron and Ames (2) .
Sterility and strain verification controls were run concurrently. All reagents, test compounds, and media were checked for sterility by plating samples of each on minimal glucose agar and incubating t-em at 370C with the test plates. The integrity of the different Salmonella strains used in the assay was verified by the following standard tests: -Lack of growth (inhibition) in the presence of crystal violet which indicates that the prerequisite alteration of the lipopolysaccharide layer of the cell wall is present.
-Growth in the presence of ampicillin-impregnated disks which indicates the presence of an ampicillin-resistant R Factor in all strains except TA1535, TA1537 and TA1538.
-Lack of growth (inhibition) following exposure to ultraviolet light which indicates the absence of the DNA excision-repair mechanism Three known mutagens were tested as positive controls to confirm the responsiveness of the strains to the mutation crocess. Each strain must be tested with at least one positive control but may be tested with several. 
Data Interpretation
According to Brusick (9), a compound is considered mutagenic if a positive dose response (correlated dose response) over three dose concentrations is achieved with at least the highest dose yielding a revertant colony count greater than or equal to ce he spontaneous colony count for the tester strains Tj," . and TAI00, or three times the spontaneous colony count ', strains TA1535, TA1537, and TA1538 (5,7). A strong coti >lated dose response in strain TAI00 without a doubling c' e individual colony count may also be considered posi-ive.
Maron and Ames (2) consider a compound mutagenic in tester strain TA97 if a correlated dose response over three concentrations is achieved with the highest dose yielding a revertant colony count greater than or equal to twice the spontaneous colony count.
Deviations from the Protocol/SOP As indicated in the protocol, strain TA104 is used as a replacement for strain TA102. This permanent change will be reflected in the next revision of the Ames SOP.
Storage of the Raw Data and Final Report
A copy of the final report, study protocols, raw data, SOPs, and an aliquot of the test compound will be retained in the LAIR archives.
RESULTS
On 4 February 1988, the toxicity of PHYSOSTIGMINE SALICYLATE was determined ( Table 1) . For this experiment all sterility, strain verification, and negative controls were normal. Exposure of the tester strain (TA100) to the two highest doses showed a decrease in the number of macrocolonies, and an observable reduction in the density of the background lawn, indicating chemical toxicity. Therefore, the highest dose selected for the mutagenicity test was 0.2 mg/plate.
Normal results were obtained for all sterility and strain verification tests during the Pmes Test performed on 4 February 1988, ( Table 2) . PHYSOSTIGMINE SALICYLATE did not induce any appreciable increase in the revertant colony counts relative to those of the negative control cultures ( Table 3) .
A tabular presentation of raw data is included in Appendix B. 
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DISCUSSION
Certain test criteria must be satisfied before an Ames test can be considered a valid assessment of a compound's mutagenic potential. First, the special features of the Ames strains must be verified. These features include demonstration of ampicillin resistance, alterations in the LP layer, and deficiency in DNA excision-repair. Second, the Salmonella strains must be susceptible to mutation by known mutagens. Third, the optimal concentration of the test compound must be determined by treating TAI00 with a broad range of doses and observing the potential toxic effects on formation of macrocolonies and microcolonies. If these tests are performed and expected data are obtained, then the results of an Ames test can be considered valid.
Since physostigmine salicylate was more potent after metabolic activation in mammalian cell assays for genotoxic potential (3,4) but was not active in the Ames test that used a standard 4% concentration of liver S-9 fraction in the activation mixture (1), a repeat of the Ames test was conducted with a higher concentration of liver S-9. Even at the recommended concentration of 10% liver S-9 fraction in the activation mixture (2), physostigmine salicylate was not active in the Ames Test. These data suggest that the genotoxic potential of physostigmine salicylate is due to chromosomal mutations as detected in the mouse lymphoma or sister chromatid exchange assays rather than gene mutations as would be detected in the Ames test.
CONCLUSION
PHYSOSTIGMINE SALICYLATE was evaluated for mutagenic potential in the Ames Test, both in the presence and absence of a 10% liver S-9 activation mixture, and did not induce a positive response under conditions of this study. 
